MILESTONE SCIENTIFIC INC.

Listed Company

MLSSCIK 0000855683NYSENon-AcceleratedSmaller ReportingOrthopedic, Prosthetic & Surgical Appliances & SuppliesDelawareFY ends Dec 31

Period

FY 2025

Revenue

—

Net Income

$-5.72M

Total Assets

—

Equity

—

Shares Out

88.08M

Op. Cash Flow

$-2.92M

Business

MILESTONE SCIENTIFIC INC. develops and commercializes computer-controlled anesthetic and drug delivery systems using its proprietary DPS Dynamic Pressure Sensing Technology®. It offers devices and disposable handpieces marketed under trademarks such as CompuFlo®, CompuDent®, The Wand®, STA Single Tooth Anesthesia System® for painless, pressure‑sensing injections, epidural guidance, and fluid aspiration. Key business areas include dental products (Wand/STA systems and handpieces) and medical products (CompuFlo Epidural System and platform extensions). The company sells via e‑commerce, direct sales, and exclusive/non‑exclusive distributors across the United States, Canada, Europe, Middle East, Latin America and other global markets.

Summary from filing dated 2025-04-15

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Product sales, net	9	9	10	9	10
Cost of products sold	3	2	3	4	4
Gross profit	6	6	7	5	6
Selling, general and administrative expenses	12	12	13	13	13
Research and development expenses	449,469	858,767	701,378	1	878,210
Depreciation and amortization expense	78,195	37,448	61,912	63,755	73,836
Total operating expenses	12	13	14	14	14
Loss from operations	−6	−7	−7	−9	−7
Interest (expense) income, net	−25,599	60,265	—	—	—
Gain on sale of net operating losses	—	2	—	—	—
Loss before provision for income taxes	−6	−5	−7	−9	—
Provision for income taxes	—	—	0	0	−333
Net loss	−6	−5	−7	−9	−7
Net loss per share applicable to common stockholders - basic	−0.07	−0.06	−0.1	−0.12	−0.1
Net loss per share applicable to common stockholders - diluted	−0.07	−0.06	—	—	−0.1
Weighted average shares outstanding and to be issued - basic	82	80	73	71	69
Weighted average shares outstanding and to be issued - diluted	82	80	—	—	69

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	1	3	3	9	15
Prepaid expenses and other current assets	468,792	564,645	517,785	443,872	375,360
Inventories	4	4	3	2	2
Advances on contracts	1	1	1	1	1
Total current assets	7	9	11	13	19
Furniture, fixtures and equipment, net	19,193	12,921	10,024	18,146	23,713
Intangibles, net	79,063	148,404	—	—	—
Right of use assets finance lease	55,811	67,201	8,998	17,645	26,294
Right of use assets operating lease	150,378	257,842	355,235	443,685	524,217
Other assets	24,150	24,150	24,150	24,150	24,150
Total assets	8	10	11	14	20
Current portion of finance lease liabilities	27,347	12,530	10,264	9,365	8,545
Current portion of operating lease liabilities	130,355	116,279	103,427	91,701	81,001
Total current liabilities	4	4	3	3	3
Non-current portion of finance lease liabilities	27,336	54,672	434	10,698	20,062
Non-current portion of operating lease liabilities	35,208	165,573	281,853	385,279	476,980
Convertible notes payable, related parties	800,000	—	—	—	—
Total liabilities	5	4	3	4	4
Commitments and contingencies	—	—	—	—	—
Common stock, par value $0.001; authorized 125,000,000 shares; 80,486,449 shares issued and 80,453,116 shares outstanding as of December 31, 2025; 78,047,798 shares issued and 78,014,465 shares outstanding as of December 31, 2024;	80,487	78,048	75,881	69,306	68,153
Additional paid in capital	137	135	132	127	125
Accumulated deficit	−134	−128	−123	−116	−108
Treasury stock, at cost, 33,333 shares	−911,516	−911,516	−911,516	−911,516	−911,516
Total Milestone Scientific, Inc. stockholders equity	3	6	8	10	16
Total liabilities and stockholders equity	8	10	11	14	20

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Depreciation expense	8,853	7,218	12,999	14,180	22,205
Amortization of intangibles	69,341	30,232	49,320	49,663	51,630
Stock based compensation	952,716	1	1	1	790,915
Bad debt expense	11,639	—	24,865	—	—
Employees paid in stock	728,750	364,953	417,500	317,265	793,110
Expense paid in stock	1	579,801	745,999	747,351	707,861
Amortization of right-of-use asset	107,463	97,393	88,450	80,533	73,552
(Increase) in accounts receivable	−216,883	−162,712	356,188	0	137,384
Increase in accounts receivable, related parties	−25,548	—	356,188	249,555	—
Increase in inventories	−68,622	−1	−1	−833,121	878,666
(Increase ) decrease in advances on contracts	−133,134	96,288	—	—	—
Decrease (increase) in prepaid expenses and other current assets	95,853	−46,860	−73,912	−68,512	40,555
Increase in accounts payable	408,856	331,789	−413,125	322,300	297,456
Increase in accounts payable, related party	866,386	82,801	−392,981	407,636	10,719
(Decrease) increase in accrued expenses	−801,116	70,610	386,882	−292,495	562,824
(Decrease) increase in accrued expenses, related party	−115,887	167,104	−30,361	−246,692	−47,493
Decrease operating right of use lease asset	−103,751	−94,991	−83,054	−72,353	81,942
Net cash used in operating activities	−3	−3	−5	−6	−4
Purchase of furniture, fixtures, and equipment	−15,124	−10,124	—	−8,527	−15,189
Sale of marketable securities	—	3	5	0	—
Net cash (used in) provided by investing activities	−15,124	3	−3	−8,527	−15,189
Net proceeds from public placement offering	—	192,156	—	—	—
Proceeds from issuance of convertible notes, related parties	800,000	—	—	—	—
Net Proceeds exercise of warrants	—	51,751	0	0	3
Payments finance lease obligations	−13,665	−10,136	−9,366	−8,544	−8,648
Net cash provided by financing activities	786,335	233,771	3	−8,544	5
Net increase (decrease) in cash and cash equivalents	−2	280,345	−6	−6	540,429
Initial recognition of finance lease-right of use asset	—	−68,340	—	—	—
Initial recognition of finance lease-right of use liabilities	—	68,340	—	—	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro